United States Peptide Cancer Vaccine Market Report & Forecast 2021-2027
Table of Contents1 Introduction to Research & Analysis Reports
1.1 Peptide Cancer Vaccine Market Definition
1.2 Market Segments
1.2.1 Segment by Pipeline
1.2.2 Segment by Application
1.3 United States Peptide Cancer Vaccine Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 United States Peptide Cancer Vaccine Overall Market Size
2.1 United States Peptide Cancer Vaccine Market Size: 2021 VS 2027
2.2 United States Peptide Cancer Vaccine Revenue, Prospects & Forecasts: 2016-2027
2.3 United States Peptide Cancer Vaccine Sales: 2016-2027
3 Company Landscape
3.1 Top Peptide Cancer Vaccine Players in United States Market
3.2 Top United States Peptide Cancer Vaccine Companies Ranked by Revenue
3.3 United States Peptide Cancer Vaccine Revenue by Companies
3.4 United States Peptide Cancer Vaccine Sales by Companies
3.5 United States Peptide Cancer Vaccine Price by Manufacturer (2016-2021)
3.6 Top 3 and Top 5 Peptide Cancer Vaccine Companies in United States Market, by Revenue in 2020
3.7 Manufacturers Peptide Cancer Vaccine Product Type
3.8 Tier 1, Tier 2 and Tier 3 Peptide Cancer Vaccine Players in United States Market
3.8.1 List of Tier 1 Peptide Cancer Vaccine Companies in United States
3.8.2 List of Tier 2 and Tier 3 Peptide Cancer Vaccine Companies in United States
4 Sights by Pipeline
4.1 Overview
4.1.1 By Pipeline - United States Peptide Cancer Vaccine Market Size Markets, 2021 & 2027
4.1.2 ITK-1
4.1.3 GRN-1201
4.1.4 TPIV200
4.1.5 TPIV110
4.1.6 UV1
4.1.7 Galinpepimut-S
4.1.8 TARP 27-35
4.1.9 HER-Vaxx
4.1.10 Vx-001
4.1.11 Others
4.2 By Pipeline - United States Peptide Cancer Vaccine Revenue & Forecasts
4.2.1 By Pipeline - United States Peptide Cancer Vaccine Revenue, 2016-2021
4.2.2 By Pipeline - United States Peptide Cancer Vaccine Revenue, 2022-2027
4.2.3 By Pipeline - United States Peptide Cancer Vaccine Revenue Market Share, 2016-2027
4.3 By Pipeline - United States Peptide Cancer Vaccine Sales & Forecasts
4.3.1 By Pipeline - United States Peptide Cancer Vaccine Sales, 2016-2021
4.3.2 By Pipeline - United States Peptide Cancer Vaccine Sales, 2022-2027
4.3.3 By Pipeline - United States Peptide Cancer Vaccine Sales Market Share, 2016-2027
4.4 By Pipeline - United States Peptide Cancer Vaccine Price (Manufacturers Selling Prices), 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - United States Peptide Cancer Vaccine Market Size, 2021 & 2027
5.1.2 Breast Cancer
5.1.3 Lung Cancer
5.1.4 Melanoma
5.1.5 Prostate Cancer
5.1.6 Others
5.2 By Application - United States Peptide Cancer Vaccine Revenue & Forecasts
5.2.1 By Application - United States Peptide Cancer Vaccine Revenue, 2016-2021
5.2.2 By Application - United States Peptide Cancer Vaccine Revenue, 2022-2027
5.2.3 By Application - United States Peptide Cancer Vaccine Revenue Market Share, 2016-2027
5.3 By Application - United States Peptide Cancer Vaccine Sales & Forecasts
5.3.1 By Application - United States Peptide Cancer Vaccine Sales, 2016-2021
5.3.2 By Application - United States Peptide Cancer Vaccine Sales, 2022-2027
5.3.3 By Application - United States Peptide Cancer Vaccine Sales Market Share, 2016-2027
5.4 By Application - United States Peptide Cancer Vaccine Price (Manufacturers Selling Prices), 2016-2027
6 Manufacturers & Brands Profiles
6.1 Boston Biomedical
6.1.1 Boston Biomedical Corporation Information
6.1.2 Boston Biomedical Overview
6.1.3 Boston Biomedical Peptide Cancer Vaccine Sales and Revenue in United States Market (2016-2021)
6.1.4 Boston Biomedical Peptide Cancer Vaccine Product Description
6.1.5 Boston Biomedical Recent Developments
6.2 Ultimovacs
6.2.1 Ultimovacs Corporation Information
6.2.2 Ultimovacs Overview
6.2.3 Ultimovacs Peptide Cancer Vaccine Sales and Revenue in United States Market (2016-2021)
6.2.4 Ultimovacs Peptide Cancer Vaccine Product Description
6.2.5 Ultimovacs Recent Developments
6.3 BrightPath Biotherapeutics
6.3.1 BrightPath Biotherapeutics Corporation Information
6.3.2 BrightPath Biotherapeutics Overview
6.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales and Revenue in United States Market (2016-2021)
6.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Description
6.3.5 BrightPath Biotherapeutics Recent Developments
6.4 TapImmune
6.4.1 TapImmune Corporation Information
6.4.2 TapImmune Overview
6.4.3 TapImmune Peptide Cancer Vaccine Sales and Revenue in United States Market (2016-2021)
6.4.4 TapImmune Peptide Cancer Vaccine Product Description
6.4.5 TapImmune Recent Developments
6.5 Immatics
6.5.1 Immatics Corporation Information
6.5.2 Immatics Overview
6.5.3 Immatics Peptide Cancer Vaccine Sales and Revenue in United States Market (2016-2021)
6.5.4 Immatics Peptide Cancer Vaccine Product Description
6.5.5 Immatics Recent Developments
6.6 Sellas
6.6.1 Sellas Corporation Information
6.6.2 Sellas Overview
6.6.3 Sellas Peptide Cancer Vaccine Sales and Revenue in United States Market (2016-2021)
6.6.4 Sellas Peptide Cancer Vaccine Product Description
6.6.5 Sellas Recent Developments
6.7 Imugene
6.7.1 Imugene Corporation Information
6.7.2 Imugene Overview
6.7.3 Imugene Peptide Cancer Vaccine Sales and Revenue in United States Market (2016-2021)
6.7.4 Imugene Peptide Cancer Vaccine Product Description
6.7.5 Imugene Recent Developments
6.8 VAXON Biotech
6.8.1 VAXON Biotech Corporation Information
6.8.2 VAXON Biotech Overview
6.8.3 VAXON Biotech Peptide Cancer Vaccine Sales and Revenue in United States Market (2016-2021)
6.8.4 VAXON Biotech Peptide Cancer Vaccine Product Description
6.8.5 VAXON Biotech Recent Developments
6.9 Generex Biotechnology
6.9.1 Generex Biotechnology Corporation Information
6.9.2 Generex Biotechnology Overview
6.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales and Revenue in United States Market (2016-2021)
6.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Description
6.9.5 Generex Biotechnology Recent Developments
6.10 ISA Pharmaceuticals
6.10.1 ISA Pharmaceuticals Corporation Information
6.10.2 ISA Pharmaceuticals Overview
6.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales and Revenue in United States Market (2016-2021)
6.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Description
6.10.5 ISA Pharmaceuticals Recent Developments
6.11 OncoTherapy Science
6.11.1 OncoTherapy Science Corporation Information
6.11.2 OncoTherapy Science Overview
6.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales and Revenue in United States Market (2016-2021)
6.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Description
6.11.5 OncoTherapy Science Recent Developments
7 United States Peptide Cancer Vaccine Production Capacity, Analysis
7.1 United States Peptide Cancer Vaccine Production Capacity, 2016-2027
7.2 Peptide Cancer Vaccine Production Capacity of Key Manufacturers in United States Market
8 Key Market Trends, Opportunity, Drivers and Restraints
8.1 Market Opportunities & Trends
8.2 Market Drivers
8.3 Market Restraints
9 Peptide Cancer Vaccine Supply Chain Analysis
9.1 Peptide Cancer Vaccine Industry Value Chain
9.2 Peptide Cancer Vaccine Upstream Market
9.3 Peptide Cancer Vaccine Downstream and Clients
9.4 Marketing Channels Analysis
9.4.1 Marketing Channels
9.4.2 Peptide Cancer Vaccine Distributors and Sales Agents in United States Market
10 Conclusion
11 Appendix
11.1 Note
11.2 Examples of Clients
11.3 Author Details
11.4 Disclaimer
List of TablesTable 1. Key Players of Peptide Cancer Vaccine in United States Market
Table 2. Top Peptide Cancer Vaccine Players in United States Market, Ranking by Revenue (2019)
Table 3. United States Peptide Cancer Vaccine Revenue by Companies, (US$, Mn), 2016-2021
Table 4. United States Peptide Cancer Vaccine Revenue Share by Companies, 2016-2021
Table 5. United States Peptide Cancer Vaccine Sales by Companies, (K Doses), 2016-2021
Table 6. United States Peptide Cancer Vaccine Sales Share by Companies, 2016-2021
Table 7. Key Manufacturers Peptide Cancer Vaccine Price (2016-2021) & (USD/Dose)
Table 8. Manufacturers Peptide Cancer Vaccine Product Type
Table 9. List of Tier 1 Peptide Cancer Vaccine Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 Peptide Cancer Vaccine Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. Major Manufacturers of ITK-1
Table 12. Major Manufacturers of GRN-1201
Table 13. By Pipeline - United States Peptide Cancer Vaccine Revenue, (US$, Mn), 2021 & 2027
Table 14. By Pipeline - United States Peptide Cancer Vaccine Revenue (US$, Mn), 2016-2021
Table 15. By Pipeline - United States Peptide Cancer Vaccine Revenue (US$, Mn), 2022-2027
Table 16. By Pipeline - United States Peptide Cancer Vaccine Sales (K Doses), 2016-2021
Table 17. By Pipeline - United States Peptide Cancer Vaccine Sales (K Doses), 2022-2027
Table 18. By Application - United States Peptide Cancer Vaccine Revenue, (US$, Mn), 2021 VS 2027
Table 19. By Application - United States Peptide Cancer Vaccine Revenue (US$, Mn), 2016-2021
Table 20. By Application - United States Peptide Cancer Vaccine Revenue (US$, Mn), 2022-2027
Table 21. By Application - United States Peptide Cancer Vaccine Sales (K Doses), 2016-2021
Table 22. By Application - United States Peptide Cancer Vaccine Sales (K Doses), 2022-2027
Table 23. Boston Biomedical Corporation Information
Table 24. Boston Biomedical Description and Major Businesses
Table 25. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Revenue (US$, Mn) and Gross Margin (USD/Dose) (2016-2021)
Table 26. Boston Biomedical Peptide Cancer Vaccine Product
Table 27. Boston Biomedical Recent Developments
Table 28. Ultimovacs Corporation Information
Table 29. Ultimovacs Description and Major Businesses
Table 30. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Revenue (US$, Mn) and Gross Margin (USD/Dose) (2016-2021)
Table 31. Ultimovacs Peptide Cancer Vaccine Product
Table 32. Ultimovacs Recent Developments
Table 33. BrightPath Biotherapeutics Corporation Information
Table 34. BrightPath Biotherapeutics Description and Major Businesses
Table 35. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$, Mn) and Gross Margin (USD/Dose) (2016-2021)
Table 36. BrightPath Biotherapeutics Peptide Cancer Vaccine Product
Table 37. BrightPath Biotherapeutics Recent Developments
Table 38. TapImmune Corporation Information
Table 39. TapImmune Description and Major Businesses
Table 40. TapImmune Peptide Cancer Vaccine Sales (K Doses), Revenue (US$, Mn) and Gross Margin (USD/Dose) (2016-2021)
Table 41. TapImmune Peptide Cancer Vaccine Product
Table 42. TapImmune Recent Developments
Table 43. Immatics Corporation Information
Table 44. Immatics Description and Major Businesses
Table 45. Immatics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$, Mn) and Gross Margin (USD/Dose) (2016-2021)
Table 46. Immatics Peptide Cancer Vaccine Product
Table 47. Immatics Recent Developments
Table 48. Sellas Corporation Information
Table 49. Sellas Description and Major Businesses
Table 50. Sellas Peptide Cancer Vaccine Sales (K Doses), Revenue (US$, Mn) and Gross Margin (USD/Dose) (2016-2021)
Table 51. Sellas Peptide Cancer Vaccine Product
Table 52. Sellas Recent Developments
Table 53. Imugene Corporation Information
Table 54. Imugene Description and Major Businesses
Table 55. Imugene Peptide Cancer Vaccine Sales (K Doses), Revenue (US$, Mn) and Gross Margin (USD/Dose) (2016-2021)
Table 56. Imugene Peptide Cancer Vaccine Product
Table 57. Imugene Recent Developments
Table 58. VAXON Biotech Corporation Information
Table 59. VAXON Biotech Description and Major Businesses
Table 60. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Revenue (US$, Mn) and Gross Margin (USD/Dose) (2016-2021)
Table 61. VAXON Biotech Peptide Cancer Vaccine Product
Table 62. VAXON Biotech Recent Developments
Table 63. Generex Biotechnology Corporation Information
Table 64. Generex Biotechnology Description and Major Businesses
Table 65. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Revenue (US$, Mn) and Gross Margin (USD/Dose) (2016-2021)
Table 66. Generex Biotechnology Peptide Cancer Vaccine Product
Table 67. Generex Biotechnology Recent Developments
Table 68. ISA Pharmaceuticals Corporation Information
Table 69. ISA Pharmaceuticals Description and Major Businesses
Table 70. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Revenue (US$, Mn) and Gross Margin (USD/Dose) (2016-2021)
Table 71. ISA Pharmaceuticals Peptide Cancer Vaccine Product
Table 72. ISA Pharmaceuticals Recent Developments
Table 73. OncoTherapy Science Corporation Information
Table 74. OncoTherapy Science Description and Major Businesses
Table 75. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Revenue (US$, Mn) and Gross Margin (USD/Dose) (2016-2021)
Table 76. OncoTherapy Science Peptide Cancer Vaccine Product
Table 77. OncoTherapy Science Recent Developments
Table 78. Peptide Cancer Vaccine Production Capacity (K Doses) of Key Manufacturers in United States Market, 2019-2021 (K Doses)
Table 79. United States Peptide Cancer Vaccine Capacity Market Share of Key Manufacturers, 2019-2021
Table 80. Peptide Cancer Vaccine Market Opportunities & Trends in United States Market
Table 81. Peptide Cancer Vaccine Market Drivers in United States Market
Table 82. Peptide Cancer Vaccine Market Restraints in United States Market
Table 83. Peptide Cancer Vaccine Raw Materials
Table 84. Peptide Cancer Vaccine Raw Materials Suppliers in United States Market
Table 85. Typical Peptide Cancer Vaccine Downstream
Table 86. Peptide Cancer Vaccine Downstream Clients in United States Market
Table 87. Peptide Cancer Vaccine Distributors and Sales Agents in United States Market
List of FiguresFigure 1. Peptide Cancer Vaccine Product Picture
Figure 2. Peptide Cancer Vaccine Segment by Pipeline
Figure 3. Peptide Cancer Vaccine Segment by Application
Figure 4. United States Peptide Cancer Vaccine Market Overview: 2020
Figure 5. United States Peptide Cancer Vaccine Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. United States Peptide Cancer Vaccine Revenue, 2016-2027 (US$, Mn)
Figure 7. Peptide Cancer Vaccine Sales in United States Market: 2016-2027 (K Doses)
Figure 8. The Top 3 and 5 Players Market Share by Peptide Cancer Vaccine Revenue in 2020
Figure 9. ITK-1 Product Picture
Figure 10. GRN-1201 Product Picture
Figure 11. TPIV200 Product Picture
Figure 12. TPIV110 Product Picture
Figure 13. UV1 Product Picture
Figure 14. By Pipeline - United States Peptide Cancer Vaccine Sales Market Share, 2016-2027
Figure 15. By Pipeline - United States Peptide Cancer Vaccine Revenue Market Share, 2016-2027
Figure 16. By Pipeline - United States Peptide Cancer Vaccine Price (USD/Dose), 2016-2027
Figure 17. Breast Cancer
Figure 18. Lung Cancer
Figure 19. Melanoma
Figure 20. Prostate Cancer
Figure 21. Others
Figure 22. By Application - United States Peptide Cancer Vaccine Sales Market Share, 2016-2027
Figure 23. By Application - United States Peptide Cancer Vaccine Revenue Market Share, 2016-2027
Figure 24. By Application - United States Peptide Cancer Vaccine Price (USD/Dose), 2016-2027
Figure 25. Boston Biomedical Peptide Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 26. Ultimovacs Peptide Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 27. BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 28. TapImmune Peptide Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 29. Immatics Peptide Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 30. Sellas Peptide Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 31. Imugene Peptide Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 32. VAXON Biotech Peptide Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 33. Generex Biotechnology Peptide Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 34. ISA Pharmaceuticals Peptide Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 35. OncoTherapy Science Peptide Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 36. United States Peptide Cancer Vaccine Production Capacity (K Doses), 2016-2027
Figure 37. Peptide Cancer Vaccine Industry Value Chain
Figure 38. Marketing Channels